Quick Facts

• Primary Use: Supports the prevention of pregnancy.
• Other Potential Uses: May assist in managing heavy or painful menstrual periods.
• Other Potential Uses: May contribute to the improvement of mild to moderate acne.

Femoden is a widely utilized combined hormonal contraceptive (CHC) containing synthetic versions of the hormones estrogen and progestogen. Its primary therapeutic domain is in providing oral contraception to prevent pregnancy.

In addition to its main function, the use of this medication may confer certain non-contraceptive benefits that support patient well-being.

Clinically, this product is also an option for women who seek assistance with symptoms related to the menstrual cycle. It may help to regulate periods and reduce the severity of heavy bleeding or menstrual pain in some individuals. Furthermore, this type of formulation may contribute to the improvement of mild to moderate acne.

All patients considering this medication should consult with a qualified professional to understand the benefits and risks. The collective benefits of combined hormonal contraceptives, including those with gestodene and ethinylestradiol, continue to outweigh the known risks when used for contraception.

Regulatory References

1. EMA therapeutic overview

Femoden's eligibility profile is strictly defined by regulatory criteria for Combined Oral Contraceptives, primarily concerning risks of thromboembolism. Use is explicitly contraindicated in several populations. These include women over 35 years of age who smoke, and those with a history of venous or arterial thromboembolism (such as DVT, PE, stroke, or heart attack). Contraindications also extend to women with known hereditary clotting disorders, active severe liver disease or liver tumors, uncontrolled severe hypertension, diabetes with vascular complications, and known or suspected breast cancer or other hormone-sensitive tumors.

The medicine is contraindicated during pregnancy and not recommended while breastfeeding. Regulatory rules establish that initiation must be delayed until at least four weeks postpartum in non-breastfeeding women. Use is also restricted, requiring cessation at least four weeks prior to and two weeks after major surgery involving prolonged immobilization. The medicine is not indicated for use after menopause.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Femoden, based on authoritative government regulatory documents, including constraints and prohibitions necessary to maintain the drug’s effectiveness and safety profile.

Formal Contraindications for Combination

The use of Femoden is formally contraindicated with specific antiviral treatments, including combinations containing Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir or Glecaprevir/Pibrentasvir. These combinations are prohibited due to the risk of serious increases in liver enzyme levels. Additionally, regulatory documents classify cigarette smoking in women aged 35 years and older as a formal contraindication due to a significantly elevated risk of serious cardiovascular events.

Interactions Affecting Hormone Levels

Many interactions are based on the impact on hormone levels. Medicines categorized as Hepatic Enzyme Inducers (such as Rifampicin, Carbamazepine, and Phenytoin) are officially stated to increase the clearance of Femoden’s active ingredients, leading to a reduction in contraceptive efficacy. The herbal product St. John’s Wort (Hypericum perforatum) is documented to cause a similar effect via enzyme induction.

Conversely, substances like Ascorbic acid (Vitamin C) may officially increase the blood concentration of Ethinyl Estradiol by interfering with metabolic processes.

Time-Dependent Restrictions

Efficacy may be compromised if factors like vomiting or severe diarrhea occur within 4 hours of taking the tablet. Regulatory information advises that non-hormonal precautions are necessary under these time-dependent circumstances.

Femoden, a combined hormonal agent, modulates reproductive physiology through the actions of its components, gestodene and ethinylestradiol.

Gestodene, a synthetic progestin, acts as a potent agonist at the progesterone receptor (PR) in target tissues, including the hypothalamus, pituitary gland, and reproductive tract. Its primary central action is to exert a negative feedback effect on the hypothalamic-pituitary-ovarian (HPO) axis. This feedback suppresses the secretion of gonadotropin-releasing hormone (GnRH), which, in turn, inhibits the pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This profound suppression prevents the requisite mid-cycle LH surge, thereby inhibiting ovarian follicular maturation and subsequent ovulation.

Concurrently, gestodene modulates the cervical environment by increasing the viscosity and decreasing the volume of cervical mucus, mechanically impeding sperm transit. It also induces morphological changes in the endometrium, including stromal pseudodecidualization and glandular atrophy.

Ethinylestradiol, the estrogen component, potentiates the action of the progestin, primarily by stabilizing the endometrium to regulate systemic modulation and by increasing the circulating concentration of sex hormone-binding globulin (SHBG), which alters the unbound fraction of circulating sex steroids.

How to Use Femoden

Femoden is a monophasic combined oral contraceptive prescribed for use in a structured, cyclic regimen. The administration instructions are precise and detail the fixed dose, timing, and cycle length to ensure consistency.

---

Administration Scope

Element	Official Instruction
Route of administration	Oral (swallowed by mouth).
Dosing schedule	One active tablet containing 30 mcg Ethinyl Estradiol and 75 mcg Gestodene is taken daily for 21 consecutive days, followed by a 7-day tablet-free interval (or 7 inactive tablets).
Timing in relation to meals	Tablets may be taken with a little liquid; intake is not dependent on meals.
Preparation requirements	None; the coated tablet must be swallowed whole.

---

Procedural Structure and Timing

Femoden must be taken at approximately the same time each day and in the sequence indicated on the blister pack to maintain a consistent dosing interval. The first cycle of tablets should commence on the first day of the menstrual bleed.

For specific populations, tablet-taking should commence between Day 21 and Day 28 following delivery or a second-trimester abortion. Starting immediately after a first-trimester abortion requires no additional use of barrier methods.

Handling Missed Doses

Specific guidance exists for handling missed doses:

• If a tablet is missed by less than 12 hours of the scheduled time, contraceptive protection is maintained; the tablet must be taken immediately, and the schedule is continued.
• If a tablet is missed by more than 12 hours, protection may be reduced, and the procedural steps for recovery depend entirely on the week of the cycle.

This continuous, cyclic pattern of hormone administration is the essential protocol for the prescribed use of this fixed-dose medicine.

Research evidence / Overview of studies for Femoden

This section provides an overview of the official research and clinical trials that form the evidence base for Femoden, focusing on the types of studies conducted, what outcomes researchers have monitored, and areas where evidence may be limited or still emerging. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

---

Evidence for Use in Pregnancy Prevention

Research for combined oral contraceptives (COCs) containing ethinyl estradiol and gestodene has primarily been conducted using large-scale, long-term observational cohort studies and multicenter clinical trials [Source 1.5]. These studies were designed to evaluate use over many treatment cycles in healthy women of childbearing age, including adolescents after they began menstruating [Source 4.4].

The primary outcome research examined in these trials was contraceptive failure rate. This is quantified using the Pearl Index, a method that tracks the number of unintended pregnancies that occur per 100 women using the medicine for one year [Source 1.3]. Studies monitoring this combination have reported measurements of the Pearl Index for method failure (when the medicine is taken perfectly) [Source 1.5]. Research has also explored the underlying pharmacological effect of inhibiting ovulation, which is the main process that research focused on regarding its effect on preventing conception.

However, the reported Pearl Index for patient failure (typical use) is generally higher than method failure. This is due to factors such as occasionally missed pills or improper use, which is a consistent challenge associated with all oral contraceptives and remains a factor outside the scope of the medicine’s biological action [Source 1.1]. Furthermore, certainty remains low when directly comparing the Pearl Index across older and newer low-dose COC formulations, as different study designs and patient populations may influence the final reported number [Source 1.4].

---

Evidence for Non-Contraceptive Indications

This block will summarize the research that has evaluated the use of this combined oral contraceptive for specific outcomes other than pregnancy prevention, such as in studies examining menstrual symptoms or skin conditions.

Studies Examining Symptoms of Primary Dysmenorrhea

Research has studied the use of combined oral contraceptives (COCs) in research exploring outcomes related to primary dysmenorrhea, which are conditions characterized by episodes of painful menstrual periods. Studies typically included women with a history of this type of menstrual discomfort, and they were observed in trials, including Randomized Controlled Trials (RCTs) [Source 3.2].

The outcomes research examined included patient-reported outcomes describing perceived discomfort, such as pain measured using the Visual Analog Scale (VAS), and changes in the need for additional pain medication [Source 3.2]. Studies report how symptoms evolved in the observed populations, and findings indicate that the use of COCs was associated with measurements of lower pain scores over time compared to placebo or no treatment [Source 3.5]. Research has also explored whether continuous use regimens, compared to the standard cyclic use, reported patterns of fewer days with dysmenorrhea [Source 3.2].

Long-term outcomes are not fully established regarding the durability of this reported pattern beyond the standard study duration, which is typically six months [Source 3.5]. Furthermore, comparative evidence is lacking for whether the gestodene formulation offers a clear advantage over every other low-dose COC specifically for dysmenorrhea outcomes, and evidence quality varies across studies when comparing administration schedules [Source 3.2].

Studies Examining Improvement in Mild to Moderate Acne

This combination was evaluated in research exploring outcomes related to skin conditions, specifically in women seeking both contraception and management for mild to moderate acne vulgaris [Source 2.3]. The studies conducted included both Randomized Controlled Trials (RCTs) and open-label, non-comparative trials [Source 2.5].

The outcomes research monitored included clinical measurements of skin changes, such as the change in total acne lesion counts (inflammatory and non-inflammatory) and monitoring the overall acne severity grade [Source 2.3]. Studies report how symptoms evolved in the observed populations, with data showing patterns related to measurements of lower lesion counts over the course of treatment, with measurements generally taken after six consecutive cycles [Source 2.5]. Research also examined changes in hormonal levels, such as Sex Hormone Binding Globulin (SHBG), which are outcomes linked to inflammatory or irritative states.

Evidence is limited for establishing clear superiority of this formulation over all other anti-androgenic COC combinations for acne outcomes [Source 2.2]. The anti-acne findings must be contextualized by the fact that a prominent placebo effect was observed in some studies that examined dermatological conditions [Source 2.5].

---

Long-Term Evidence and Follow-Up Duration

Studies that was studied for the primary use of this combined oral contraceptive typically monitored contraceptive effectiveness over an intermediate-term duration, such as one year (13 consecutive treatment cycles) [Source 1.5]. This duration is the standard period used to characterize the Pearl Index.

For the COC class broadly, data are available over many years from large post-marketing observational studies and surveillance programs [Source 1.2]. However, there is limited information for long-term outcomes specific to non-contraceptive outcomes, where follow-up durations were typically short-to-intermediate term, often ranging from six to nine months [Source 2.3, 3.5]. This means long-term outcomes are not fully established regarding the durability of symptom patterns.

---

Evidence for Use in Specific Subpopulations

The primary research for this medicine was observed in healthy women of childbearing age, including adolescents after menarche [Source 4.4].

However, data for certain groups remain insufficient or are still emerging. Regulatory reviews of COC research have sometimes examined whether the reported Pearl Index is consistent across different subgroups, such as those defined by body weight (Body Mass Index or BMI) or racial background [Source 1.7]. Subgroup findings are uncertain in some studies, indicating that outcomes may show statistical variations across these groups. Therefore, results apply only to the populations studied and do not provide definitive evidence across all potential users [Source 1.7].

---

Research Gaps and Areas of Uncertainty

Research provides context but not individual predictions; findings describe group patterns, not personal outcomes. Evidence highlights what is known, and what is still uncertain:

• Real-World Efficacy Data: The difference between the pregnancy rates reported under perfect use in trials and the slightly higher rates seen in typical real-world use is a pattern observed for this entire class of medicine [Source 1.1].
• Comparative Evidence: Comparative evidence is lacking in some areas regarding whether the gestodene/ethinyl estradiol combination is definitively superior to other specific modern combined oral contraceptives for outcomes related to acne or dysmenorrhea [Source 2.2, 3.2].
• Long-Term Data: As noted, long-term outcomes are not fully established for non-contraceptive outcomes, as follow-up durations were limited in many of the relevant randomized trials [Source 3.5].

Common questions about Femoden (FAQ)

Q: What is the risk of Venous Thromboembolism (VTE) with Femoden and when is it highest?

Official regulatory documents indicate that the risk of VTE (a blood clot in a vein) is small with all low-dose combined hormonal contraceptives. For products containing gestodene, like Femoden, the risk is generally estimated to be slightly higher than for some older formulations. The risk is officially noted as being highest during the first year of use or when the medicine is restarted after a break of four or more weeks.

Q: What does the term "third-generation progestogen" mean?

Femoden contains Gestodene, which is classified as a third-generation progestogen. This classification is a regulatory term used to distinguish it from the older progestin hormones used in earlier oral contraceptive formulations. The distinction is based on the specific chemical structure and pharmacological profile of the hormone.

Q: What should I do if I vomit within 4 hours of taking Femoden?

If vomiting or severe diarrhea occurs within 4 hours of taking a tablet, regulatory information advises that the tablet is considered missed. In this scenario, official guidance indicates that the procedural steps for a missed dose should be followed, as contraceptive protection may be reduced.

Q: What is the exact size or appearance of the Femoden tablet?

According to the official product description found in regulatory sources, Femoden is supplied as a small, white, coated tablet. These physical characteristics are standard across the product's official labeling.

Q: Can I skip my tablet-free week to avoid getting a period?

The official product administration instructions are based on a structured, cyclic regimen involving 21 active tablets followed by a 7-day tablet-free interval. The regulatory label does not include guidance for intentionally skipping the hormone-free interval or for continuous use of the active tablets.

Q: Should I stop taking Femoden if I have breakthrough bleeding (spotting)?

Official information lists minor bleeding irregularities, such as spotting or breakthrough bleeding, as a common side effect, particularly during the first few cycles of use. If this abnormal bleeding is persistent, heavy, or recurrent, regulatory guidance advises that it should be investigated by a physician.

Official Storage and Disposal Requirements for Femoden

This information reflects the storage, handling, and disposal requirements as stated in official regulatory documents, such as the Summary of Product Characteristics (SmPC).

Requirement Type	Official Labeled Instruction
Storage Temperature	Do not store above 25 C.
Protection/Handling	Protect from light; keep in the original packaging.
Stability/Shelf Life	5 years.
Child Protection	Keep out of the sight and reach of children.
Disposal	No special requirements; dispose of any unused or expired product according to local requirements.

Femoden must be kept at or below 25 C and shielded from light to maintain product stability over its 5-year shelf life. Disposal instructions state that the medicine requires no special handling, but regulatory standards mandate that unused medication be handled and discarded based on local governmental waste regulations, rather than being flushed or thrown in household trash.